{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:33:57Z","timestamp":1773423237266,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.thromres.2008.08.010","type":"journal-article","created":{"date-parts":[[2008,10,3]],"date-time":"2008-10-03T04:31:24Z","timestamp":1223008284000},"page":"S29-S35","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S1","title":["Brave new world: The current and future use of novel anticoagulants"],"prefix":"10.1016","volume":"123","author":[{"given":"Alex C.","family":"Spyropoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2008.08.010_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543784.16.4.431","article-title":"Investigational treatments of venous thromboembolism","volume":"16","author":"Spyropoulos","year":"2007","journal-title":"Expert Opin Investig Drugs."},{"issue":"4","key":"10.1016\/j.thromres.2008.08.010_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2796.2003.01224.x","article-title":"Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa\/tissue factor","volume":"254","author":"Lee","year":"2003","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.thromres.2008.08.010_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.thromres.2008.08.010_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.thromres.2008.08.010_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.thromres.2008.08.010_bib6","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2008.08.010_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J Thromb Haemost."},{"issue":"26","key":"10.1016\/j.thromres.2008.08.010_bib8","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.thromres.2008.08.010_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2008.08.010_bib10","series-title":"The EINSTEIN-DVT dose-finding study","article-title":"Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis","author":"Buller","year":"2006"},{"issue":"12","key":"10.1016\/j.thromres.2008.08.010_bib11","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost."},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2008.08.010_bib12","article-title":"A dose finding study of the oral direct Factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis \u2013 The Botticelli Investigators","volume":"5","author":"Buller","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2008.08.010_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J Thromb Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2008.08.010_bib14","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2008.08.010_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02667.x","article-title":"Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis","volume":"62","author":"Liesenfeld","year":"2006","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2008.08.010_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2008.08.010_bib17","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9591","key":"10.1016\/j.thromres.2008.08.010_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"abigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2008.08.010_bib19","unstructured":"The RE-MOBILIZE writing committee. The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery. J Arthroplasty 2008 Apr 11 [Electronic publication ahead of print]."},{"issue":"Supplement 2","key":"10.1016\/j.thromres.2008.08.010_bib20","article-title":"The oral direct thrombin inhibitor dabigatran etexilate is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery","volume":"5","author":"Caprini","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808003368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808003368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T04:24:45Z","timestamp":1545711885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384808003368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":20,"alternative-id":["S0049384808003368"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2008.08.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}